News

BMJ3d
Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus
2 Department of Internal Medicine, General Hospital of Kufstein, Kufstein, Austria 3 Department of Internal Medicine I, Innsbruck Medical University, Innsbruck, Austria 4 Department of Internal ...
BMJ4d
Ankylosing spondylitis: an overview
1 Department of Gastroenterology and Rheumatology, Free University, Berlin, Germany 2 Rheumazentrum Ruhrgebiet, Herne, Germany and Department of Gastroenterology and Rheumatology, Free University, ...
BMJ4d
Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies
Institute of Biophysics and Informatics, First Faculty of Medicine, Charles University, Prague, Czech Republic O Kryštůfková, Institute of Rheumatology, Prague, Czech Republic, Na Slupi 4, 120 00 ...
BMJ4d
The International Classification of Functioning, Disability and Health (ICF) Core Sets for rheumatoid arthritis: a way to specify functioning
1 Department of Physical Medicine and Rehabilitation, Ludwig-Maximilians-University, Munich, Germany 2 ICF Research Branch of the WHO FIC CC (DIMDI), IMBK—Department of Physical Medicine and ...
BMJ5d
Predictors of work disability during the first 3 years after diagnosis in a national rheumatoid arthritis inception cohort
1 Section of Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden 2 Department of Orthopedics, Musculoskeletal Sciences, Clinical Sciences Lund, Lund University, Lund, Sweden 3 ...
BMJ5d
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis
Objectives To assess the efficacy and safety of abatacept, a selective T-cell costimulation modulator, in a phase III study in psoriatic arthritis (PsA). Methods This study randomised patients (1:1) ...
BMJ5d
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial
Objectives Risankizumab is an interleukin-23 inhibitor under study for the treatment of patients with psoriatic arthritis (PsA). The phase 3 KEEPsAKE 2 trial investigated the efficacy and safety of ...
BMJ6d
Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis
Objectives Short-term predictive endpoints of chronic kidney disease (CKD) are needed in lupus nephritis (LN). We tested response to therapy at 1 year. Results We studied 381 patients (90.5% ...
BMJ7d
Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis
Background Studies examining the relationship between serological status (rheumatoid factor and/or anticitrullinated antibody) and rituximab treatment outcome in rheumatoid arthritis (RA) have been ...
BMJ7d
Clinical and ultrasonographic predictors of joint replacement for knee osteoarthritis: results from a large, 3-year, prospective EULAR study
11 Paris-Descartes University, Medicine Faculty, UPRES-EA 4058 & APHP, Cochin Hospital, Rheumatology B Department, Paris, France Correspondence to Professor Maxime Dougados, Paris-Descartes University ...
BMJ8d
Imaging research results from the Osteoarthritis Initiative (OAI): a review and lessons learned 10 years after start of enrolment
The Osteoarthritis Initiative (OAI) is a multicentre, prospective, observational, cohort study of knee osteoarthritis (OA) that began recruitment in 2004. The OAI provides public access to clinical ...
BMJ8d
Predictive factors of work disability in rheumatoid arthritis: a systematic literature review
1 Coronel Institute for Occupational and Environmental Health, Academic Medical Centre, Research Institute Amsterdam Centre for Health and Health Care Research (AmCOGG), Amsterdam, The Netherlands 2 ...